. Author manuscript; available in PMC: 2014 Dec 1.

Published in final edited form as: Int J Antimicrob Agents. 2013 Aug 22;42(6):10.1016/j.ijantimicag.2013.07.009. doi: 10.1016/j.ijantimicag.2013.07.009

Table 1.

Best-fit pharmacokinetic (PK) parameters of the major polymyxin components PB1, PB2, PB3 and isoleucine-B1 (ile-PB1) following intravenous administration of polymyxin B (n = 4)

PK parameter	Component	Liposome	Solution (USP)
AUC_0–6h (mg·h/L)	PB1	4.77	2.76
	PB2	1.07	0.30
	PB3	0.39	0.33
	ile-PB1	0.64	0.64
T_1/2 (h)	PB1	0.60	0.32
	PB2	0.44	0.21
	PB3	0.30	0.28
	ile-PB1	0.42	0.29
CL (mL/h/kg)	PB1	444.10	790.06
	PB2	308.28	899.90
	PB3	489.78	664.39
	ile-PB1	562.65	575.61
V_ss (ml/kg)	PB1	382.90	373.06
	PB2	197.77	274.74
	PB3	209.87	267.30
	ilePB1	338.41	241.10

USP, US Pharmacopeia; AUC_0–6h, area under the concentration–time curve from 0–6 h; T_1/2, elimination half-life; CL, clearance; V_ss, volume of distribution at steady state.